If you have depression and it has not meaningfully improved after trying at least two different antidepressants, each taken at an indicated dose for an adequate length of time, you may already meet the most widely used definition of treatment-resistant depression (TRD).
That single sentence carries a lot of weight, so let's unpack it carefully. Knowing whether your depression qualifies as "treatment-resistant" is not an academic exercise. It changes what your insurance may cover, what treatments your care team can recommend, what represents evidence based practice for a unique circumstance in depression treatment, and how quickly relief may be possible.
"Treatment-Resistant" Depression Does Not Mean What Many People Fear
Given the intimidating name, many people hear "treatment-resistant" and assume it means “hopeless” or that they or their prescriber did something wrong, like not trying hard enough. The good news is that neither is true.
You did not "fail" the medications: the medications failed you. About one in three people with depression do not get adequate relief from oral antidepressants alone, according to a clinical review of ketamine and esketamine pharmacotherapy. That is not a character flaw or a lack of effort. It usually means the mechanism those medications use, adjusting levels of serotonin, norepinephrine, and dopamine, is not the lever your depression responds to.
"I just don't want to feel this way and I don't want to wait for months and months and months to feel better. That's what treatment-resistant means in real human terms." — Dr. Ben Yudkoff, Co-Founder and Chief Medical Officer, Lumin Health
Here is the part that surprises most people: the evidence-based threshold for TRD is lower than they assume. You do not need a decade of suffering or an exhaustive list of medications behind you. If you have given two antidepressants a fair try in your current episode without adequate relief, you may already be there and eligible for treatments that are specifically designed to help where other antidepressant medications trials are unlikely to. Recognizing that earlier matters, because it extends access to evidence-based interventional options to people who could benefit from them.
The Working Definition of Treatment-Resistant Depression
There is no single universal definition of TRD, but the most commonly used one, and the one that insurance companies typically use when approving coverage esketamine (Spravato) for adults with treatment-resistant depression, looks like this:
- A diagnosis of major depressive disorder. TRD is a description of how your depression has responded to treatment, not a separate illness.
- At least two different antidepressants tried in your current depressive episode. Different medications, not just dose changes of the same one.
- Each trial was "adequate." The medication was taken at a therapeutic dose, for a long enough period, with reasonable consistency.
- Symptoms did not adequately improve. You may have felt somewhat better and then plateaued, or felt no change at all.
What counts as an "adequate trial" for depression medications?
An adequate trial generally means a therapeutic dose taken for several weeks, often six to eight, since antidepressants act slowly. Two weeks at a starting dose that was abandoned does not usually count, and neither does a medication you stopped after a few days because of side effects.
This cuts both ways. Some people believe they have "tried everything" when their trials may have been too short to count, or the dose of the medication was not adequately adjusted while assessing efficacy. Others assume they have not tried enough, when their two solid trials already meet the bar. A review of personalized ketamine and esketamine treatment underscores why this history-taking matters: matching the right intervention to the right person starts with an accurate accounting of what has actually been tried.
What about the "current depressive episode" requirement?
Definitions typically count trials within your current depressive episode. At times, it can be difficult to understand the full scope of an episode, especially if you have never experienced a true period of remission. If your depression has ebbed without ever fully lifting, do not try to adjudicate this yourself. This is exactly the kind of boundary question a psychiatric evaluation is built to answer.
Signs It May Be Time to Ask About Treatment-Resistant Depression
Consider bringing this up with a provider if several of these sound familiar:
- You have taken two or more different antidepressants and still do not feel like yourself
- Dose increases or medication switches produce brief hope, then a plateau
- You felt partial relief, but the heaviness, flatness, or hopelessness never fully lifted
- Your provider has started discussing "augmentation," which is when a second medication is added to boost the first
- You find yourself measuring life in months of waiting: waiting for the next medication to kick in, then the next
- Friends or family have watched you cycle through medications without lasting change
None of these alone confirms TRD. Together, they are a strong signal that it is worth asking the question directly: "Does my history meet the criteria for treatment-resistant depression?"
Why the Definition Matters: Insurance and Access to Treatments like Esketamine (Spravato)
The clinical definition of two adequate trials is not a universal truth that every payer accepts. Insurance companies add their own nuance. Some plans require more than two medication trials before covering interventional treatment, while others require that an augmenting agent was tried. Some ask for documentation of behavioral interventions like psychotherapy.
This is why working with a team that handles prior authorization every day matters. At Lumin Health, navigating those payer-specific definitions is part of the work we do for every person we treat, from the first evaluation through authorization and follow-up. You can review the plans we work with on our insurance page, or check your coverage with our eligibility form.
One important exception to the two-trial framework:
"If you're experiencing suicidal thoughts with depression, the insurance companies will typically cover esketamine (Spravato) without needing to have had prior antidepressant trials. You don't need to have taken any other requisite number of antidepressants." — Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
If you are having thoughts of suicide right now, please reach out to a professional for immediate support. You can call or text 988 to reach the Suicide & Crisis Lifeline, any hour, any day.
What Becomes Possible Once Treatment Resistant Depression Is Recognized
Meeting the definition of TRD is not a dead end. It is the moment the treatment menu expands beyond the medication class that has not worked for you.
Evidence-based interventional options for TRD include esketamine (Spravato), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), and partial hospitalization programs. Each has a different profile, and the right fit is a conversation between you and your care team about what the evidence suggests and what you prefer.
At Lumin Health, we focus on two of these pathways:
- Esketamine (Spravato) is FDA-approved for adults with treatment-resistant depression and major depression with suicidal thoughts. It is a nasal spray taken in a certified healthcare setting under medical supervision, used along with an oral antidepressant. Learn more on our esketamine (Spravato) page.
- Intramuscular (IM) ketamine is an evidence-based, off-label application of a medicine that has been in use for over 50 years. It is a mixture containing both the S-ketamine and R-ketamine molecules. You can read more on our ketamine therapy page.
"Ketamine acts on glutamate, which is entirely different from the serotonin system that SSRIs target. That's why it can work for people who haven't responded to traditional antidepressants." — Dr. Ben Yudkoff, Chief Medical Officer, Lumin Health
Research on ketamine in depressive episodes shows that relief, when it comes, can arrive in days rather than the weeks an oral antidepressant requires. No treatment works for everyone, and we will never promise otherwise. But for people whose depression has not adequately responded to antidepressants, a treatment that works through an entirely different mechanism is often the first genuinely new option in years.
Both treatments happen under psychiatric care, with vital signs like blood pressure and the oxygen saturation of your blood monitored throughout, a post-treatment observation period, and a plan for a ride home. A thorough medical evaluation comes first, every time.
Frequently Asked Questions
How common is treatment-resistant depression?
Roughly one in three people treated for major depression do not get adequate relief from oral antidepressants alone. TRD is common enough that an entire field of interventional psychiatry exists to address it.
Is treatment-resistant depression permanent?
No. "Treatment-resistant" describes how your depression has responded to one class of treatment so far. It says nothing about how you may respond to treatments that work through different mechanisms.
Do I need to have tried psychotherapy to have treatment-resistant depression?
Most clinical definitions center on medication trials, not therapy. Some insurance plans do ask about psychotherapy history when authorizing treatment, which is one more reason to work with a team experienced in navigating those requirements.
Can I have treatment-resistant depression if antidepressants helped a little?
Yes. Partial response without adequate relief still counts toward most definitions. Feeling 30 percent better is not the goal of depression treatment. Remission is.
Talking With a Provider About What Comes Next
If you recognized yourself in this article, consider bringing these questions to your next appointment, or to a new evaluation: How many adequate antidepressant trials do I have in my current episode? Do I meet the criteria for treatment-resistant depression? What interventional options does that open up?
Lumin Health is a psychiatrist-led practice based out of the Boston Metro and the DC/Maryland/Virginia areas and expanding to other states. Our academically-affiliated providers have walked through this exact question with hundreds of people, including young adults navigating TRD and people evaluating whether Spravato is a fit. If you would like help making sense of your treatment history, we would be grateful to walk with you toward relief. Explore whether an evaluation may be a fit for you.
.svg)
